Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-02-11
1994-12-27
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 99, A61K 31445, C07D22110
Patent
active
053766644
ABSTRACT:
This invention relates to unsymmetrical mono-3-nitro bis-naphthalimides of formula ##STR1## including (R,R)-2-{2-[2-((2-(1,3-dioxo-1H-benz[de]isoquinolin-2-(3H)-yl)-propylamino ))ethylamino]-1-methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-dione, processes for their preparation, pharmaceutical compositions containing them, and methods of using them to treat cancer, particularly solid tumor carcinomas, in mammals.
REFERENCES:
patent: 4841052 (1989-06-01), Harnisch et al.
patent: 4874863 (1989-10-01), Brana et al.
patent: 4919848 (1990-04-01), Harnisch
patent: 5206249 (1993-04-01), Sun
Cherney Robert J.
Kaltenbach III Robert F.
Seitz Steven P.
Sun Jung-Hui
Ferguson Blair Q.
Hydorn Michael B.
Richter Johann
The Du Pont Merck Pharmaceutical Company
LandOfFree
Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-919957